clinical trial · NCT05051527
Study to Evaluate the Effectiveness of Legalon®
Non-alcoholic Fatty Liver Disease (NAFLD)Legalon® 140 mg
brief summary
This is a multinational, multicentre, prospective, non-interventional study (NIS) in non-alcoholic fatty liver disease (NAFLD) patients with concomitant metabolic syndrome treated with Legalon® combined with diet and exercise.
started
Aug 8, 2022
primary completion
Oct 31, 2024
completion
Oct 31, 2024
last updated
Sep 30, 2025
official title
Observational, Single Arm, Prospective Study to Evaluate the Effectiveness of Legalon® in Addition to Diet and Exercise in Reducing Plasma Levels of Liver Enzymes
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol